In this month’s issue of PME magazine we balance the changes that are already the theme of 2017 with some much needed stability in the form of a look at family-owned or foundation-run pharmaceutical companies.
Such European businesses include Germany’s Boehringer Ingelheim, Italy’s Chiesi and Denmark’s LEO Pharma, whose president and CEO Gitte Aabo talked to us about playing the long game and how this sees it through times of boom and bust.
The stability of a firm like LEO, established as a Copenhagen pharmacy in 1908 and still following its founding principles, contrasts with the uncertainty that appears to assail us on most other fronts.
To pick just one example, the meeting between Donald Trump and the heads of Celgene, Lilly, Merck & Co and Novartis showed the new US president continuing with his rhetoric about medicine prices, while promising looser regulations – whether pharma’s in favour of them or not.
Meanwhile, his words on the ‘global freeloading’ of foreign drug price controls and how they cut into US pharmaceutical firm’s profits are sure to have raised eyebrows at IQWiG, HAS, NICE and elsewhere.
• View the February 2017 issue of PME online